Tenofovir Alafenamide

Release time:2017-10-28 08:25:58

       Tenofovir Alafenamide (TAF). Its main component is tenofovir aramidamine semi-fumarate. English name: Tenofovir Alafenamide  

       CAS: 379270-37-8
       Molecular formula: C21H29N6O5P
       Molecular weight: 476.465921

      Tenofovir alafenamide fumarate (TAF) is a novel nucleoside reverse transcriptase inhibitor (NRTI). In clinical trials, the drug has been shown to be lower than that of Gillard The marketed drug Viread (tenofovir dipivoxil fumarate tablets, Viread, TDF) one-tenth of the dose, it has a very high antiviral effect, while improving renal function and bone parameters.

       As Gillard's Viread will expire in patent protection in 2017, Gillard is working to advance TAF's approval and hopes to be approved before the Viread patent expires to ensure its competitiveness in the HIV market. Gilead Scientific (MPP, Medicines Patent Pool) reached an important agreement to allow India and China to produce the company's anti-HIV (HIV) and anti-hepatitis B virus (HBV) drug generic drug - tenofovir Amine (TAF). At the 20th World AIDS Conference in Melbourne, Australia, Gillard announced the decision and said the agreement with the drug pool was aimed at promoting its new drug TAF against HIV and hepatitis B virus, but This agreement has yet to be approved by TAF US regulators. According to the agreement, according to this agreement, the drug patent pool has the right to TAF permission to India and China's generic drug production company, by these companies to produce drugs and sold to 112 developing countries.

       In order to focus on the future development of our company, the company has started to develop the new drug fumaric acid leptophan ammonia (TAF) in 2015, and it is progressing smoothly. The experiment has entered the final stage of demolition, and it is expected that 2017 TAF can complete all the experimental work, and preparation for pilot. At present, the main domestic research and development in the TAF enterprises for the Shanghai Bozhi research new drug Technology Co., Ltd. and Nanjing germination Chemical Co., Ltd., and so a few companies. The use of the drug dose is small, can replace TDF to reduce renal damage, is to enhance the upgrade version of TDF, the future must be a new generation of anti-viral drugs instead of TDF.